SELLAS Life Sciences Group, Inc. (SLS)Healthcare | Biotechnology | New York, United States | NasdaqCM
13.21 USD
-2.00
(-13.149%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.47 +0.26 (1.968%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:37 a.m. EDT
The immediate outlook is driven by a high-conviction momentum play centered on an imminent clinical trial readout. The stock has rallied significantly from its lows, yet the options chain reveals a speculative frenzy with heavy call buying at $20 and $30 targets, suggesting the market is pricing in a 'potentially company-defining' success. However, this excitement masks a precarious fundamental reality: the company is burning cash with negative free cash flow and no earnings, trading at a massive premium to book value despite a historically terrible trajectory where the share price has lost nearly 99.99% of its value over the last decade. While the short-term catalyst could drive a parabolic move, the long-term investment case remains neutral due to the absence of sustainable profitability or a proven track record of value creation, leaving investors exposed to the risk of a failed trial followed by a return to the mean. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.144127 |
| MSTL | 0.168348 |
| AutoETS | 0.188152 |
| AutoARIMA | 0.309194 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.199 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.535 |
| Market Cap | 2,667,702,784 |
| Forward P/E | -132.10 |
| Beta | 2.49 |
| Website | https://sellaslifesciences.com |
As of Aug. 22, 2026, 3:37 a.m. EDT: Speculators are aggressively positioning for a binary event, evidenced by massive volume spikes in out-of-the-money calls at $20 and $30 strikes alongside significant put volume at deep strikes ($4-$10). The open interest walls at the money ($15) suggest a crowded trade expecting volatility expansion around a catalyst, while the lack of intrinsic value in many strikes indicates bets on a gap-up rather than steady appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | 6.2185793 |
| Address1 | 7 Times Square |
| Address2 | Suite 2503 |
| All Time High | 718,500.0 |
| All Time Low | 0.5 |
| Ask | 13.27 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 8,611,240 |
| Average Daily Volume3 Month | 8,412,228 |
| Average Volume | 8,412,228 |
| Average Volume10Days | 8,611,240 |
| Beta | 2.494 |
| Bid | 13.0 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.682 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.21 |
| Current Ratio | 18.827 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.79 |
| Day Low | 13.15 |
| Debt To Equity | 0.535 |
| Display Name | SELLAS Life Sciences |
| Dividend Date | 1,573,171,200 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 2,530,096,896 |
| Eps Current Year | -0.2 |
| Eps Forward | -0.1 |
| Eps Trailing Twelve Months | -0.22 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.3368 |
| Fifty Day Average Change | 0.8732004 |
| Fifty Day Average Change Percent | 0.07078014 |
| Fifty Two Week Change Percent | 621.8579 |
| Fifty Two Week High | 15.88 |
| Fifty Two Week High Change | -2.67 |
| Fifty Two Week High Change Percent | -0.16813603 |
| Fifty Two Week Low | 1.39 |
| Fifty Two Week Low Change | 11.82 |
| Fifty Two Week Low Change Percent | 8.503597 |
| Fifty Two Week Range | 1.39 - 15.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,205,328,600,000 |
| Float Shares | 201,148,023 |
| Forward Eps | -0.1 |
| Forward P E | -132.09999 |
| Free Cashflow | -16,378,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Fullday Change | -2.0 |
| Fullday Change Percent | -13.1492 |
| Fullday Price | 13.47 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00922 |
| Held Percent Institutions | 0.36859 |
| Implied Shares Outstanding | 201,945,709 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,573,171,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. |
| Long Name | SELLAS Life Sciences Group, Inc. |
| Market | us_market |
| Market Cap | 2,667,702,784 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_262231850 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -32,461,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,072,603,962 |
| Number Of Analyst Opinions | 2 |
| Open | 14.7 |
| Operating Cashflow | -28,423,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 646 200 5278 |
| Post Market Change | 0.26000023 |
| Post Market Change Percent | 1.9682076 |
| Post Market Price | 13.47 |
| Post Market Time | 1,787,961,594 |
| Previous Close | 15.21 |
| Price Eps Current Year | -66.049995 |
| Price Hint | 2 |
| Price To Book | 19.369501 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.278 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -2.0 |
| Regular Market Change Percent | -13.1492 |
| Regular Market Day High | 14.79 |
| Regular Market Day Low | 13.15 |
| Regular Market Day Range | 13.15 - 14.79 |
| Regular Market Open | 14.7 |
| Regular Market Previous Close | 15.21 |
| Regular Market Price | 13.21 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 9,757,807 |
| Return On Assets | -0.23299 |
| Return On Equity | -0.39633998 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 201,945,709 |
| Shares Percent Shares Out | 0.2791 |
| Shares Short | 56,371,865 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 55,280,869 |
| Short Name | SELLAS Life Sciences Group, Inc |
| Short Percent Of Float | 0.28030002 |
| Short Ratio | 8.9 |
| Source Interval | 15 |
| State | NY |
| Symbol | SLS |
| Target High Price | 35.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 32.5 |
| Target Median Price | 32.5 |
| Total Cash | 138,343,008 |
| Total Cash Per Share | 0.685 |
| Total Debt | 737,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.4975 |
| Two Hundred Day Average Change | 6.7125 |
| Two Hundred Day Average Change Percent | 1.0330896 |
| Type Disp | Equity |
| Volume | 9,757,807 |
| Website | https://sellaslifesciences.com |
| Zip | 10,036 |